Cancer clinical trials in the region Pays de la Loire
449 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT04305496
#2019-003629-78
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
1 recruiting site
AstraZeneca
Phase 3
Lung cancer
#NCT05984277
#2023-503298-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
1 recruiting site
AstraZeneca
Phase 3
Rectal cancer
#NCT06402864
#2023-506885-30-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT06943872
#2024-517131-52-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
Phase 3
Lung cancer
#NCT06908993
#2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS non G12C
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3
Lymphoma
#NCT05947851
#2022-501560-17-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
CLL & Richter's syndrome
#NCT05947851
#2022-501560-17-01
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Targeted therapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Colon cancer
Rectal cancer
#NCT06293625
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
57 recruiting sites
CHU Dijon
Phase 3
Colon cancer
#NCT05855200
#2023-503265-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSS/pMMR
9 recruiting sites
GlaxoSmithKline
Phase 3
Colon cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
3 recruiting sites
CHU Rouen